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Abstract
The use of antimycotic drugs in fungal infections is based on the concept that they suppress fungal growth by a direct
killing effect. However, amphotericin and nystatin have been reported to also trigger interleukin-1b (IL-1b) secretion in
monocytes but the molecular mechanism is unknown. Here we report that only the polyene macrolides amphotericin B,
nystatin, and natamycin but none of the tested azole antimycotic drugs induce significant IL-1b secretion in-vitro in
dendritic cells isolated from C57BL/6 mouse bone marrow. IL-1b release depended on Toll-like receptor-mediated
induction of pro-IL-1b as well as the NLRP3 inflammasome, its adaptor ASC, and caspase-1 for enzymatic cleavage of pro-
IL-1b into its mature form. All three drugs induced potassium efflux from the cells as a known mechanism for NLRP3
activation but the P2X7 receptor was not required for this process. Natamycin-induced IL-1b secretion also involved
phagocytosis, as cathepsin activation as described for crystal-induced IL-1b release. Together, the polyene macrolides
amphotericin B, nystatin, and natamycin trigger IL-1b secretion by causing potassium efflux from which activates the
NLRP3-ASC-caspase-1. We conclude that beyond their effects on fungal growth, these antifungal drugs directly activate
the host’s innate immunity.
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Introduction
Innate immunity encompasses multiple strategies to impair the
growth of fungi on external surfaces and in internal compartments
of multicellular organisms. Innate pattern recognition receptors
(PRRs) have the potential to detect and translate the recognition of
fungal components into the transcription of NF-kB-dependent
cytokines which triggers multiple aspects of host defense [1]. For
example, fungal components like b-glucans and zymosans are the
principle cell wall components of Candida, Aspergillus, S.
cerevisiae and other fungi spp. are the potent pathogen associated
molecular patterns to trigger different PRRs include toll-like
receptors (TLRs) and C-type lectin receptors [1,2]. The non-TLR
PRRs, include dectin-1, mannose receptor, the Fcc-coupled
receptors Dectin2 and mincle, DC-SIGN, Galectin-3 and the
scavenger receptors. The recognition and phagocytic internaliza-
tion of fungal PAMPs by C-type lectins co-operates with TLR1, -2,
-4 and -6 to activate MyD88 as well as spleen tyrosine kinase
(SYK)/CARD9 signalling to produce numerous pro-inflammatory
cytokines and chemokines.
Antimycotic drugs have dramatically improved the morbidity
and mortality related to fungal infections. Antimycotics in clinical
use encompass semisynthetic or fully synthetic compounds that
have the capacity to kill fungi which substantially supports the
host’s immune system to eradicate the pathogen. As such
antimycotic drugs and the host’s immune defense act synergisti-
cally to control fungal infections. In this process dying fungi release
additional agonists for pattern recognition receptors, therefore the
early phase of antifungal therapy involves an additional activation
of innate host defense. Interestingly, certain polyene antimycotic
drugs like nystatin and amphotericin B have been reported to be
able to directly induce interleukin-1beta (IL-1b) secretion in
human peripheral blood mononuclear cells (PBMCs) and
macrophages but the molecular mechanisms are still unknown
[3,5].
The activation of IL-1b secretion differs from that of other NF-
kB-dependent cytokines as TLR- or C-type lectin signaling
activates NF-kB to induce the expression of pro-IL-1b. In contrast
to most other cytokines, the subsequent secretion of IL-1b requires
a second signal, like inflammasome-mediated activation of
caspase-1, also referred to as IL-1b converting enzyme [6]. Four
inflammasomes have been described to integrate the various
endogenous and exogenous triggers of caspase-1 activation, i.e.
NLRP1, NLRP3, IPAF and AIM2 [6–9]. Of those, NLRP1 and
NLRP3 were recently shown to be activated by microbial toxins.
For example, Bacillus anthracis lethal toxin can activate caspase-1
via the NLRP1 inflammasome or pore forming toxins mitotoxin,
vibrio toxins (V.cholerae, V.vulnificus) and bacterial ionophores
nigericin, streptolysin O, and a, b and c- hemolysins as well as
muramyl dipeptides can activate NLRP3-mediated caspase-1
activation [10–12]. We therefore questioned whether synthetic
antimycotic drugs have a similar potential to activate inflamma-
some- and caspase-1-mediated release of IL-1b as a mechanism to
trigger innate immunity.
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19588Antifungal Drugs and Inflammasome Activation
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19588Results
Distinct polyene macrolide antifungal drugs activate
dendritic cells and macrophages to secrete mature IL-1b
To address a putative immunostimulatory potential, we first
exposed LPS-primed bone marrow derived dendritic cells
(BMDCs) to selected members of commonly used antifungal drugs
and measured IL-1b production in cell culture supernatants after
6 hours of stimulation. Among all compounds tested only the
polyene macrolides amphotericin B, natamycin, and nystatin
induced high levels of IL-1b into BMDC supernatants (Figure 1A).
Members of the azole antifungal drugs were far less potent to
induce IL-1b secretion; therefore, we focussed on the polyene
macrolides in the further experiments. This effect depended on
priming with LPS (Figure S1) which provides the necessary signal
for the induction of pro-IL-1b [6]. Similar results were obtained in
BM-derived macrophages (Figure 1B).
Amphotericin B, natamycin, and nystatin activate the
NLRP3 inflammasome-ASC-caspase-1 to trigger IL-1b
secretion
Various compounds such as crystals, pore-forming bacterial
toxins or ATP induce IL-1b secretion by activating the NLRP3
inflammasome [13]. We therefore exposed amphotericin B,
nystatin, and natamycin to BMDCs isolated from NLRP3-
deficient or wildtype mice. Lack of NLRP3 almost completely
abrogated IL-1b release upon stimulation with all three antifungals
(Figure 1C). The remaining signal detected by IL-1b ELISA might
represent extracellular pro-IL-1b. To address this possibility, we
performed immunoblotting of cell culture supernatants to dissect
the pro-IL-1b from the cleaved IL-1b (p17). In addition,
immunoblotting for the p10 subunit of caspase-1 in cell culture
supernatants of wildtype and NLRP3-deficient cells was performed
to study caspase-1 activation. Stimulation with all three antifungals
induced the caspase-1 cleaving product p10 in wildtype cells but
not in supernatants of NLRP3-deficient cells, documenting that
NLRP3 is required for drug-induced caspase-1 activation
(Figure 1D). NLRP3 needs the adaptor ASC to activate caspase-
1 [13]. In fact, lack of ASC as well as the pancaspase inhibitor Z-
VAD-FMK abrogated IL-1b release in BMDC upon stimulation
with all three antifungal drugs (Figure 2A and 2B). Thus, IL-1b
secretion induced by amphotericin B, nystatin, and natamycin
involves the NLRP3-ASC-caspase-1 pathway.
Mechanism of NLRP3 inflammasome activation by
polyene macrolide antifungal drugs
Several models of NLRP3 activation have been described, i.e.
P2X7- and potassium flux-dependent pore formation [14],
endosomal rupture involving cytosolic cathepsin B activity [15],
and oxidative stress [16]. As some antifungals were shown to
destabilize cell membranes and thereby promote potassium efflux
[17–19], we first exposed BMDCs to medium containing 75mM
potassium chloride which reduces potassium efflux. IL-1b
secretion was abrogated upon stimulation with ATP as well as
with amphotericin B, nystatin, and natamycin while a high
extracellular concentration of NaCl had no effect (Figure 2C). To
further confirm the effect of potassium efflux caused by these drugs
in IL-1b induction, we treated cells with Quinidine, a potassium
channel inhibitor. IL-1b secretion was significantly decreased with
all drugs except for ATP (Figure S2). However, ATP-induced IL-
1b secretion was different from that of the antifungal drugs
because ATP-induced IL-1b secretion required the P2X7 receptor
[14] while all three antifungal drugs could induce IL-1b release in
P2X7-deficient BMDCs (Figure 2D), suggesting that all three
drugs could directly trigger potassium efflux without activating
P2X7, as most likely by introducing pores into the cell membrane
[17–19].
The release of lysosomal proteases as a result of phagocytosis-
dependent lysosome destabilization has also been implicated in
NLRP3 activation [15]. In order to assess whether these antifungal
drugs act through this pathway, we exposed BMDCs to all three
antifungals in the presence or absence of the phagocytosis inhibitor
cytochalasin D. Interestingly, cytochalasin D reduced IL-1b
release only by natamycin, but did not influence IL-1b production
by amphotericin and nystatin (Figure 2E). In addition, inhibition
of cathepsin B by CA-074-Me, a specific inhibitor also produced
the same results (Figure 2F), suggesting that only natamycin is
involved in the lysosomal pathway to induce IL-1b production.
It has been shown that fungal ligands induce ROS and thereby
activate NLRP3 inflammasome [16,20,21]. To determine the role
of these drugs in NLRP3 activation, we treated LPS-prestimulated
BMDCs with the antioxidant N-acetyl cysteine (NAc) followed by
drug stimulation. Interestingly, NAc treatment significantly
reduced the IL-1b production only by natamycin, but not by
other drugs from the same group, suggesting that natamycin
triggers IL-1b secretion in a different manner from that of
amphothericn and nystatin.
Together Amphotericin B, nystatin, and natamycin activate the
NLRP3 inflammasome through different ways but all are
dependent on potassium efflux.
Discussion
Our data show that polyene macrolide antimycotic drugs,
namely amphotericin B, nystatin, and natamycin, activate the
NLRP3-inflammsome- and caspase-1-mediated secretion of IL-1b
in dendritic cells. IL-1b secretion will elicit secondary effects after
IL-1R activation, hence, these antimycotic drugs have the
potential to trigger innate immunity. This is remarkable in two
ways: First, these compounds are known to inhibit fungal growth
directly but our data show that they also might suppress fungal
growth indirectly via activating innate host defense. Second, when
used as an antifungal drug clinically, the immunostimulatory
potential might contribute to the well known toxicity with these
drugs. Azoles were far less potent as compared to polyene
macrolides in inducing IL-1b secretion in dendritic cells, therefore,
we focussed on this class of antimycotic drugs [3–5]. The polyene
macroplids nystatin and amphotericin B had previously been
reported to induce IL-1b relase in hPBMCs [5] and also in
macrophages upon stimulation [22]. However, the mechanism
how these drugs can trigger IL-1b release remained enigmatic.
IL-1b secretion requires two independent signals: First, the
induction of pro-IL-b is a NF-kB-dependent process which
Figure 1. Amphotericin B, nystatin, and natamycin trigger IL-1b secretion via NLRP3. (A) LPS primed murine BMDCs and (B) macrophages
were stimulated with antimycotic drugs as indicated at a concentration of 50 mg/ml; supernatants were collected 6 hours later, and IL-1b release was
assessed by ELISA. ATP was used as a positive control. (C) LPS prestimulated wildtype or NLRP3-deficient BMDCs were exposed to amphotericin B,
nystatin, and natamycin at a concentration of 50 mg/ml; supernatants were collected 6 hours later, and IL-1b release was assessed by ELISA. ATP was
used as a positive control. (D) Immunoblot analysis of mature IL-1b (p17) and caspase-1 cleavage product (p10) in wildtype and NLRP3-deficient
BMDCs stimulated with the drugs. Data are means 6 SD from three independent experiments all performed in triplicate. p,0.05 versus medium.
doi:10.1371/journal.pone.0019588.g001
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signaling pathways leading to the degradation of IkB and the
translocation of relA/relB to the nucleus [6]. Nystatin was
previously reported to induce pro-inflammatory cytokines via
TLR1/TLR2 signaling [3] but we found that nystatin, as well as
amphotericin B and natamycin, required LPS prestimulation to
induce pro-IL-1b as a prerequisite for IL-1b secretion. Hence, or
data argue against a direct agonistic role of these drugs on TLRs.
The second step that is required for IL-1b secretion is the
activation of caspase-1, an enzymatic step that cleaves off mature
IL-1b from its pro-form. Our data clearly show that the NLRP3
inflammasome and ASC are necessary for polyene macrolides to
activate caspase-1. NLRP3 is known to translate multiple stimuli
into ASC-dependent caspase-1 activation [6]. So far three major
danger signal pathways are known to convergate into the
activation of NLRP3, i.e., potassium efflux through membrane
pores, oxidative stress, and lysosomal destabilization with cytosolic
cathepsin activity [6]. Our data clearly document that amphoter-
icin B, nystatin, and natamycin all cause potassium efflux from
dendritic cells, potentially by introducing membrane pores [17–19],
which we found as a mandatory step for subsequent NLRP3
activation. This process did not involve P2X7 receptor which is
consistent with previous descriptions of other NLRP3 agonists
such as streptolysin O, hemolysins, and fungal components
[20,23]. However, the three antimycotic drugs differed in terms
of the involvement of additional ways to activate NLRP3.
Natamycin but not amphotericin B or nystatin involved the
phagocytic uptake mechanims and cathepsin acitvity as it has been
descfribed for various NLRP3-activating crystals [24]. Further-
more, ROS inhibition partially inhibited natamycin-induced IL-
1b secretion as it has been described for high glucose, C. albicans,
hemazoin and MSU crystals [13] as stimulators of intracellular
oxidative stress [24].
Together, amphotericin B, nystatin, and natamycin have the
potential to trigger IL-1b secretion in dendritic cells and
macrophages by activating the NLRP3 inflammasome and ASC-
mediated caspase-1 activation through potassium efflux. Thus, it is
conceivable that these antimycotic drugs can directly activate
innate immunity of the host conceptually similar to pathogen-
associated molecular patterns.
Methods
Cell culture and reagents
Bone marrow-derived dendritic cells (BMDCs) and macrophag-
es were isolated from 6 week old C57BL/6 mice (Jackson Labs,
Bar Harbor, Maine) by established protocols. In some experiments
BMDCs were prepared from NLRP3- [13], ASC- [8] or P2X7-
deficient mice [25]. Cells were cultured in RPMI 1640 medium
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS (v/
v, Biochrom KG), 1% of penicillin and streptomycin (PAA
Laboratories, Pasching, Austria). All cells were stimulated in serum
free RPMI 1640 medium at a density of 1610
6 cells per ml. Cells
were pre-stimulated with ultrapure LPS (50 ng/ml, Invivogen,
San Diego, CA, USA) for 3hours and later cells were stimulated
for 6 hours with antimycotic drugs (50 mg/ml, Sigma, Steinheim
Germany), ATP (5mM) and MSU (250 mg/ml). Inhibitors such as
Z-VAD-FMK (20 mM, all from Invivogen), cytochalasin D
(5 mM), CA-074-Me (10 mM, Calbiochem, Darmstadt, Germany),
NAC (10mM, Sigma) and Quinidine (250 mM, Sigma) were added
30min before antifungals stimulation. KCl (75 mM) was used to
increase extracellular K+ concentration and NaCl (75mM) as a
positive control.
Measurement of cytokines
Mouse cytokines were measured in cell-free culture superna-
tants for IL-1b by ELISA from BD Biosciences Pharmingen (San
Diego, CA, USA). Assays were performed in triplicate for each
independent experiment.
Immunoblotting
Cell-free culture supernatants were concentrated with Amicon
ultra filters (Millipore, Billerica, MA) for standard immunoblot
analysis as described [26]. Primary antibodies were polyclonal goat
antibody to mouse-IL-1b (R&D Systems, Minneapolis, MN) and
poly clonal rabbit antibody to anti-caspase-1 (sc-514, Santa Cruz,
CA, USA).
Statistical analysis
Data were expressed as mean 6 standard deviation (SD).
Comparison between two groups was performed by two-tailed
t-test. A value of p,0.05 was considered to be statistically
significant. All statistical analyses were calculated using GraphPad
Prism.
Supporting Information
Figure S1 A. Antimycotic drugs-induced IL-1 b produc-
tion depends on LPS prestimulation. Wildtype BMDCs
were primed with or without LPS (50ng/ml) for 3 hours. Cells
were stimulated with 50 mg/mL concentration of each amphoter-
icin B, nystatin, and natamycin. IL-1b secretion was measured in
supernatants after 6 hours of stimulation. Data are means 6 SD
from three independent experiments all performed in triplicate.
p,0.05 versus medium. B. Antimycotic drugs-induced IL-1b
production depends on Potassium efflux. LPS (50ng/ml)
primed BMDCs were treated with Quinidine (250 mM) for 30mins
before cells were stimulated with 50 mg/mL concentration of each
amphotericin B, nystatin, and natamycin. IL-1b secretion was
measured in supernatants after 6 hours of stimulation. Data are
means 6 SD from three independent experiments all performed in
triplicate. p,0.05 versus medium.
(TIF)
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